Paul C Boutros

List of Publications by Year in Descending Order

341 papers	19,964 citations	64 h-index	134 g-index
390 ext. papers	26,466 ext. citations	10.9 avg, IF	7.85 L-index

#	Paper	IF	Citations
341	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium.. *European Urology Open*	0.9	1
340	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.. *JAMA Oncology*, **2022**,	13.4	2
339	Optimization of small extracellular vesicle isolation from expressed prostatic secretions in urine for in-depth proteomic analysis.. *Journal of Extracellular Vesicles*, **2022**, 11, e12184	16.4	1
338	Age influences on the molecular presentation of tumours.. *Nature Communications*, **2022**, 13, 208	17.4	1
337	Data-driven identification of inherent features of eukaryotic stress-responsive genes.. *NAR Genomics and Bioinformatics*, **2022**, 4, lqac018	3.7	
336	Introduction and expression of PIK3CA in a papillary thyroid cancer BRAF cell line leads to a dedifferentiated aggressive phenotype.. *Journal of Otolaryngology - Head and Neck Surgery*, **2022**, 51, 7	5.4	1
335	Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy.. *Nature Communications*, **2022**, 13, 1898	17.4	0
334	Establishment of four Head and Neck Squamous Cell Carcinoma Cell Lines: Importance of Reference DNA is Essential for accurate genomic characterization.. *Journal of Laryngology and Otology*, **2022**, 1-21	1.8	
333	Impact of Exercise on Susceptibility and Severity of COVID-19 in Patients with Cancer: A Retrospective Study.. *Cancer Epidemiology Biomarkers and Prevention*, **2022**, 31, 1036-1042	4	
332	Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena.. *Journal of Hematology and Oncology*, **2022**, 15, 48	22.4	0
331	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.. *JAMA Network Open*, **2021**, 4, e2138550	10.4	3
330	Loss of CDCP1 triggers FAK activation in detached prostate cancer cells. *American Journal of Clinical and Experimental Urology*, **2021**, 9, 350-366	1.6	
329	The telomere length landscape of prostate cancer. *Nature Communications*, **2021**, 12, 6893	17.4	0
328	A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol. *Canadian Journal of Kidney Health and Disease*, **2021**, 8, 20543581211057708	2.3	0
327	Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors. *Cancer Research*, **2021**, 81, 5833-5848	10.1	2
326	Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. *Nature Communications*, **2021**, 12, 6248	17.4	3
325	Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing. *Cancer*, **2021**,	6.4	1

324	CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer. *Nature Communications*, **2021**, 12, 1781	17.4	6
323	Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. *Cell*, **2021**, 184, 2239-2254.e39	56.2	57
322	Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression. *Scientific Reports*, **2021**, 11, 7434	4.9	1
321	NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4. *Science Advances*, **2021**, 7,	14.3	3
320	Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review. *European Urology Open Science*, **2021**, 27, 77-87	0.9	
319	All HPV-negative head and neck cancers are not the same: Analysis of the TCGA dataset reveals that anatomical sites have distinct mutation, transcriptome, hypoxia, and tumor microenvironment profiles. *Oral Oncology*, **2021**, 116, 105260	4.4	5
318	Copy Number Profiles of Prostate Cancer in Men of Middle Eastern Ancestry. *Cancers*, **2021**, 13,	6.6	1
317	A proteomic investigation of isogenic radiation resistant prostate cancer cell lines. *Proteomics - Clinical Applications*, **2021**, 15, e2100037	3.1	2
316	Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. *European Urology*, **2021**, 79, 762-771	10.2	13
315	Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study. *Npj Breast Cancer*, **2021**, 7, 90	7.8	
314	Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. *BJU International*, **2021**, 127, 96-107	5.6	3
313	Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. *Radiotherapy and Oncology*, **2021**, 154, 207-213	5.3	6
312	Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier. *European Urology*, **2021**, 79, 107-111	10.2	6
311	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. *Journal of the National Cancer Institute*, **2021**, 113, 742-751	9.7	39
310	Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. *Nature Cell Biology*, **2021**, 23, 87-98	23.4	53
309	A practical guide to cancer subclonal reconstruction from DNA sequencing. *Nature Methods*, **2021**, 18, 144-155	21.6	25
308	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. *European Urology*, **2021**, 80, 632-640	10.2	14
307	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. *JAMA Network Open*, **2021**, 4, e2115312	10.4	1

306	Decreased ATM Protein Expression Is Substantiated with PTEN Loss in Defining Aggressive Phenotype of Prostate Cancer Associated with Lethal Disease. *European Urology Open Science*, **2021**, 29, 93-101	0.9	1
305	A community challenge to evaluate RNA-seq, fusion detection, and isoform quantification methods for cancer discovery. *Cell Systems*, **2021**, 12, 827-838.e5	10.6	3
304	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. *European Urology*, **2021**, 80, 142-146	10.2	3
303	A clinically applicable integrative molecular classification of meningiomas. *Nature*, **2021**, 597, 119-125	50.4	25
302	Sex Differences in Cancer Genomes: Much Learned, More Unknown. *Endocrinology*, **2021**, 162,	4.8	2
301	Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry. *Nature Reviews Urology*, **2021**, 18, 707-724	5.5	4
300	Aging of the progenitor cells that initiate prostate cancer. *Cancer Letters*, **2021**, 515, 28-35	9.9	2
299	HLA-A02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses.. *Cell Reports*, **2021**, 37, 110167	10.6	1
298	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis.. *JAMA Network Open*, **2021**, 4, e2139769	10.4	2
297	Quantifying the influence of mutation detection on tumour subclonal reconstruction. *Nature Communications*, **2020**, 11, 6247	17.4	5
296	Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression. *OncoImmunology*, **2020**, 9, 1851950	7.2	2
295	Urinary biomarkers in prostate cancer: to the miRnome and beyond. *Translational Andrology and Urology*, **2020**, 9, 843-845	2.3	
294	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. *European Urology*, **2020**, 78, 327-332	10.2	9
293	A robust benchmark for detection of germline large deletions and insertions. *Nature Biotechnology*, **2020**, 38, 1347-1355	44.5	98
292	Sex disparities in head & neck cancer driver genes: An analysis of the TCGA dataset. *Oral Oncology*, **2020**, 104, 104614	4.4	7
291	Targeted Mass Spectrometry of a Clinically Relevant PSA Variant from Post-DRE Urines for Quantitation and Genotype Determination. *Proteomics - Clinical Applications*, **2020**, 14, e2000012	3.1	4
290	Candidate Cancer Driver Mutations in Distal Regulatory Elements and Long-Range Chromatin Interaction Networks. *Molecular Cell*, **2020**, 77, 1307-1321.e10	17.6	20
289	Optimization and expansion of non-negative matrix factorization. *BMC Bioinformatics*, **2020**, 21, 7	3.6	16

288	Integrative pathway enrichment analysis of multivariate omics data. *Nature Communications*, **2020**, 11, 735	17.4	53
287	Divergent mutational processes distinguish hypoxic and normoxic tumours. *Nature Communications*, **2020**, 11, 737	17.4	46
286	The evolutionary history of 2,658 cancers. *Nature*, **2020**, 578, 122-128	50.4	307
285	Pan-cancer analysis of whole genomes. *Nature*, **2020**, 578, 82-93	50.4	840
284	Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. *Nature Genetics*, **2020**, 52, 331-341	36.3	168
283	Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer. *Nature Communications*, **2020**, 11, 441	17.4	21
282	Transcriptomics in RCC. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 742-754	2.8	3
281	The landscape of RNA polymerase II-associated chromatin interactions in prostate cancer. *Journal of Clinical Investigation*, **2020**, 130, 3987-4005	15.9	14
280	Analysis of the TCGA Dataset Reveals that Subsites of Laryngeal Squamous Cell Carcinoma are Molecularly Distinct. *Cancers*, **2020**, 13,	6.6	1
279	Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. *European Urology*, **2020**, 77, 201-208	10.2	21
278	A community effort to create standards for evaluating tumor subclonal reconstruction. *Nature Biotechnology*, **2020**, 38, 97-107	44.5	35
277	miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA. *Cancer Letters*, **2020**, 473, 107-117	9.9	16
276	Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer. *Oral Oncology*, **2020**, 101, 104529	4.4	4
275	TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3K□nhibition in head and neck squamous cell carcinoma. *Journal of Experimental and Clinical Cancer Research*, **2020**, 39, 217	12.8	5
274	The DNA methylation landscape of advanced prostate cancer. *Nature Genetics*, **2020**, 52, 778-789	36.3	71
273	Community Assessment of the Predictability of Cancer Protein and Phosphoprotein Levels from Genomics and Transcriptomics. *Cell Systems*, **2020**, 11, 186-195.e9	10.6	11
272	Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training. *PLoS ONE*, **2020**, 15, e0238593	3.7	2
271	Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models. *PLoS ONE*, **2020**, 15, e0239315	3.7	3

270	Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. *European Urology Oncology*, **2020**,	6.7	6
269	Sex differences in oncogenic mutational processes. *Nature Communications*, **2020**, 11, 4330	17.4	23
268	Systematic Assessment of Tumor Purity and Its Clinical Implications. *JCO Precision Oncology*, **2020**, 4,	3.6	7
267	Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation. *PLoS Medicine*, **2020**, 17, e1003281	11.6	8
266	Temporal Stability and Prognostic Biomarker Potential of the Prostate Cancer Urine miRNA Transcriptome. *Journal of the National Cancer Institute*, **2020**, 112, 247-255	9.7	13
265	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. *European Urology Oncology*, **2020**, 3, 80-91	6.7	11
264	Transgenerational epigenetic and transcriptomic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure in rat. *Archives of Toxicology*, **2020**, 94, 1613-1624	5.8	4
263	Mutational analysis of head and neck squamous cell carcinoma stratified by smoking status. *JCI Insight*, **2019**, 4,	9.9	15
262	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. *European Urology*, **2019**, 76, 693-702	10.2	12
261	Comparative toxicoproteogenomics of mouse and rat liver identifies TCDD-resistance genes. *Archives of Toxicology*, **2019**, 93, 2961-2978	5.8	2
260	Reproducible biomedical benchmarking in the cloud: lessons from crowd-sourced data challenges. *Genome Biology*, **2019**, 20, 195	18.3	10
259	Rethinking Lupus Nephritis Classification on a Molecular Level. *Journal of Clinical Medicine*, **2019**, 8,	5.1	8
258	Genome-wide germline correlates of the epigenetic landscape of prostate cancer. *Nature Medicine*, **2019**, 25, 1615-1626	50.5	25
257	What Is Oligometastatic Prostate Cancer?. *European Urology Focus*, **2019**, 5, 159-161	5.1	17
256	BPG: Seamless, automated and interactive visualization of scientific data. *BMC Bioinformatics*, **2019**, 20, 42	3.6	31
255	Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer. *European Urology*, **2019**, 76, 18-23	10.2	30
254	ONECUT2 is a driver of neuroendocrine prostate cancer. *Nature Communications*, **2019**, 10, 278	17.4	72
253	PDGFRα+ stromal adipocyte progenitors transition into epithelial cells during lobulo-alveologenesis in the murine mammary gland. *Nature Communications*, **2019**, 10, 1760	17.4	20

252	RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer. *Journal of Translational Medicine*, **2019**, 17, 125	8.5	9
251	Transcriptomic Impact of IMA-08401, a Novel AHR Agonist Resembling Laquinimod, on Rat Liver. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	1
250	A readout of metabolic efficiency in arylamine N-acetyltransferase-deficient mice reveals minor energy metabolism changes. *FEBS Letters*, **2019**, 593, 831-841	3.8	1
249	The Proteogenomic Landscape of Curable Prostate Cancer. *Cancer Cell*, **2019**, 35, 414-427.e6	24.3	97
248	Best practices for benchmarking germline small-variant calls in human genomes. *Nature Biotechnology*, **2019**, 37, 555-560	44.5	125
247	Widespread and Functional RNA Circularization in Localized Prostate Cancer. *Cell*, **2019**, 176, 831-843.e22	36.2	214
246	The influence of BRCA2 mutation on localized prostate cancer. *Nature Reviews Urology*, **2019**, 16, 281-290	5.5	36
245	2,3,7,8-Tetrachlorodibenzo-p-dioxin modifies alternative splicing in mouse liver. *PLoS ONE*, **2019**, 14, e0219747	3.7	4
244	A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer. *Prostate* , **2019**, 79, 1705-1714	4.2	19
243	MicroRNA-198 suppresses prostate tumorigenesis by targeting MIB1. *Oncology Reports*, **2019**, 42, 1047-1056	3.5	11
242	Landscape of transcriptomic interactions between breast cancer and its microenvironment. *Nature Communications*, **2019**, 10, 3116	17.4	12
241	Raman microscopy for the identification of an aggressive variant of prostate cancer, intraductal carcinoma of the prostate. *Annals of Oncology*, **2019**, 30, v25-v26	10.3	2
240	Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors. *Cancer Cell*, **2019**, 36, 674-689.e6	24.3	21
239	Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort. *Translational Lung Cancer Research*, **2019**, 8, 167-175	4.4	4
238	Modelling the MYC-driven normal-to-tumour switch in breast cancer. *DMM Disease Models and Mechanisms*, **2019**, 12,	4.1	8
237	The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. *Nature Communications*, **2019**, 10, 5251	17.4	66
236	Genomic and human papillomavirus profiling of an oral cancer cohort identifies TP53 as a predictor of overall survival. *Cancers of the Head & Neck*, **2019**, 4, 5	5.9	6
235	A transcriptome-based signature of pathological angiogenesis predicts breast cancer patient survival. *PLoS Genetics*, **2019**, 15, e1008482	6	7

234	Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapy-Resistant Early Breast Cancers.. *JCO Precision Oncology*, **2019**, 3, 1-13	3.6	
233	Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. *International Journal of Radiation Oncology Biology Physics*, **2019**, 103, 84-91	4	20
232	A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3K inhibition in controlling tumor growth. *International Journal of Cancer*, **2019**, 145, 2100-2106	7.5	16
231	Molecular landmarks of tumor hypoxia across cancer types. *Nature Genetics*, **2019**, 51, 308-318	36.3	255
230	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. *European Urology*, **2019**, 75, 523-531	10.2	33
229	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. *Nature Genetics*, **2018**, 50, 682-692	36.3	112
228	The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. *Cell*, **2018**, 173, 1003-1013.e15	56.2	115
227	Pathogenic Germline Variants in 10,389 Adult Cancers. *Cell*, **2018**, 173, 355-370.e14	56.2	342
226	NanoStringNormCNV: pre-processing of NanoString CNV data. *Bioinformatics*, **2018**, 34, 1034-1036	7.2	2
225	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. *EBioMedicine*, **2018**, 31, 182-189	8.8	67
224	Mutations in Mitochondrial DNA From Pancreatic Ductal Adenocarcinomas Associate With Survival Times of Patients and Accumulate as Tumors Progress. *Gastroenterology*, **2018**, 154, 1620-1624.e5	13.3	15
223	Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: Clinical/pathologic associations and etiologic mechanisms. *PLoS ONE*, **2018**, 13, e0196117	3.7	25
222	Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19. *Cell*, **2018**, 174, 564-575.e18	56.2	154
221	Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. *BMC Cancer*, **2018**, 18, 8	4.8	54
220	Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer. *Journal of Ovarian Research*, **2018**, 11, 27	5.5	19
219	Germline contamination and leakage in whole genome somatic single nucleotide variant detection. *BMC Bioinformatics*, **2018**, 19, 28	3.6	5
218	Mammary molecular portraits reveal lineage-specific features and progenitor cell vulnerabilities. *Journal of Cell Biology*, **2018**, 217, 2951-2974	7.3	20
217	Somatic mutations in early onset luminal breast cancer. *Oncotarget*, **2018**, 9, 22460-22479	3.3	15

216	High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines. *Oncotarget*, **2018**, 9, 26064-26071	3.3	11
215	Pathway-based subnetworks enable cross-disease biomarker discovery. *Nature Communications*, **2018**, 9, 4746	17.4	19
214	A comparative study of survival models for breast cancer prognostication revisited: the benefits of multi-gene models. *BMC Bioinformatics*, **2018**, 19, 400	3.6	3
213	Combining accurate tumor genome simulation with crowdsourcing to benchmark somatic structural variant detection. *Genome Biology*, **2018**, 19, 188	18.3	29
212	Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models. *PLoS ONE*, **2018**, 13, e0207152	3.7	12
211	MYC Protein Interactome Profiling Reveals Functionally Distinct Regions that Cooperate to Drive Tumorigenesis. *Molecular Cell*, **2018**, 72, 836-848.e7	17.6	62
210	Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. *Cancer Cell*, **2018**, 34, 996-1011.e8	24.3	89
209	MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis. *Cancer Cell*, **2018**, 34, 579-595.e8	24.3	52
208	Sex Differences in Cancer Driver Genes and Biomarkers. *Cancer Research*, **2018**, 78, 5527-5537	10.1	58
207	Neutral tumor evolution?. *Nature Genetics*, **2018**, 50, 1630-1633	36.3	38
206	Valection: design optimization for validation and verification studies. *BMC Bioinformatics*, **2018**, 19, 339	3.6	1
205	Prediction of early breast cancer patient survival using ensembles of hypoxia signatures. *PLoS ONE*, **2018**, 13, e0204123	3.7	7
204	MYC dephosphorylation by the PP1/PNUTS phosphatase complex regulates chromatin binding and protein stability. *Nature Communications*, **2018**, 9, 3502	17.4	23
203	miRNA-106a and prostate cancer radioresistance: a novel role for LITAF in ATM regulation. *Molecular Oncology*, **2018**, 12, 1324-1341	7.9	29
202	2,3,7,8 Tetrachlorodibenzo-p-dioxin-induced RNA abundance changes identify Ackr3, Col18a1, Cyb5a and Glud1 as candidate mediators of toxicity. *Archives of Toxicology*, **2017**, 91, 325-338	5.8	4
201	Genomic hallmarks of localized, non-indolent prostate cancer. *Nature*, **2017**, 541, 359-364	50.4	320
200	Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. *Nature Communications*, **2017**, 8, 13671	17.4	128
199	The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. *Journal of Thoracic Oncology*, **2017**, 12, 850-859	8.9	64

198	A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. *European Urology*, **2017**, 72, 665-674	10.2	98
197	Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine. *Npj Breast Cancer*, **2017**, 3, 3	7.8	10
196	Pdxdc1 modulates prepulse inhibition of acoustic startle in the mouse. *Translational Psychiatry*, **2017**, 7, e1125	8.6	7
195	Comparison of pre-processing methods for Infinium HumanMethylation450 BeadChip array. *Bioinformatics*, **2017**, 33, 3151-3157	7.2	7
194	Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	12
193	Enhancing knowledge discovery from cancer genomics data with Galaxy. *GigaScience*, **2017**, 6, 1-13	7.6	6
192	Mining Human Prostate Cancer Datasets: The "camcAPP" Shiny App. *EBioMedicine*, **2017**, 17, 5-6	8.8	20
191	Pro- and anti-inflammatory cytokine associations with major depression in cancer patients. *Psycho-Oncology*, **2017**, 26, 2149-2156	3.9	16
190	Mapping genomic and transcriptomic alterations spatially in epithelial cells adjacent to human breast carcinoma. *Nature Communications*, **2017**, 8, 1245	17.4	10
189	Cytokines and depression in cancer patients and caregivers. *Neuropsychiatric Disease and Treatment* , **2017**, 13, 2903-2911	3.1	6
188	Detecting protein variants by mass spectrometry: a comprehensive study in cancer cell-lines. *Genome Medicine*, **2017**, 9, 62	14.4	30
187	Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer. *Oncotarget*, **2017**, 8, 4668-4689	3.3	58
186	LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. *Cancer Research*, **2017**, 77, 5479-5490	10.1	53
185	Mitochondrial mutations drive prostate cancer aggression. *Nature Communications*, **2017**, 8, 656	17.4	66
184	TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. *Nature Genetics*, **2017**, 49, 1336-1345	36.3	105
183	Compendium of TCDD-mediated transcriptomic response datasets in mammalian model systems. *BMC Genomics*, **2017**, 18, 78	4.5	15
182	Kronos: a workflow assembler for genome analytics and informatics. *GigaScience*, **2017**, 6, 1-10	7.6	7
181	Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. *International Journal of Cancer*, **2017**, 140, 662-673	7.5	44

180	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. *European Urology*, **2017**, 72, 22-31	10.2	28
179	Nanocall: an open source basecaller for Oxford Nanopore sequencing data. *Bioinformatics*, **2017**, 33, 49-55	7.2	83
178	novoBreak: local assembly for breakpoint detection in cancer genomes. *Nature Methods*, **2017**, 14, 65-67	21.6	67
177	Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer. *Oncotarget*, **2017**, 8, 71512-71519	3.3	18
176	Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. *Oncotarget*, **2017**, 8, 74036-74048	3.3	10
175	The Clinical Genomics of Prostate Cancer **2017**, 97-110		1
174	Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. *Nature Genetics*, **2016**, 48, 1142-50	36.3	158
173	Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer. *Nature Communications*, **2016**, 7, 11906	17.4	59
172	VennDiagramWeb: a web application for the generation of highly customizable Venn and Euler diagrams. *BMC Bioinformatics*, **2016**, 17, 401	3.6	18
171	BAMQL: a query language for extracting reads from BAM files. *BMC Bioinformatics*, **2016**, 17, 305	3.6	11
170	A bedr way of genomic interval processing. *Source Code for Biology and Medicine*, **2016**, 11, 14	1.9	11
169	Log::ProgramInfo: A Perl module to collect and log data for bioinformatics pipelines. *Source Code for Biology and Medicine*, **2016**, 11, 9	1.9	0
168	MYC interaction with the tumor suppressive SWI/SNF complex member INI1 regulates transcription and cellular transformation. *Cell Cycle*, **2016**, 15, 1693-705	4.7	29
167	Current and Evolving Methods to Visualize Biological Data in Cancer Research. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	13
166	PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma. *Journal of Translational Medicine*, **2016**, 14, 67	8.5	28
165	Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer. *Breast Cancer Research*, **2016**, 18, 16	8.3	16
164	A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis. *PLoS Computational Biology*, **2016**, 12, e1004890	5	21
163	A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial. *Oncotarget*, **2016**, 7, 49099-49106	3.3	2

162	PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. *PLoS ONE*, **2016**, 11, e0153954	3.7	53
161	Clonality of localized and metastatic prostate cancer. *Current Opinion in Urology*, **2016**, 26, 219-24	2.8	7
160	Crowdsourced estimation of cognitive decline and resilience in Alzheimer□s disease. *Alzheimerjs and Dementia*, **2016**, 12, 645-53	1.2	58
159	Allele-Skewed DNA Modification in the Brain: Relevance to a Schizophrenia GWAS. *American Journal of Human Genetics*, **2016**, 98, 956-962	11	17
158	A genome-wide association study of non-HPV-related head and neck squamous cell carcinoma identifies prognostic genetic sequence variants in the MAP-kinase and hormone pathways. *Cancer Epidemiology*, **2016**, 42, 173-80	2.8	2
157	The parameter sensitivity of random forests. *BMC Bioinformatics*, **2016**, 17, 331	3.6	60
156	Comparing continuous and discrete analyses of breast cancer survival information. *Genomics*, **2016**, 108, 78-83	4.3	3
155	A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis. *Arthritis Research and Therapy*, **2016**, 18, 218	5.7	18
154	Matching Kidneys and Urines: Establishing Noninvasive Surrogates of Intrarenal Events in Primary Glomerulonephritis. *Seminars in Nephrology*, **2015**, 35, 256-65	4.8	1
153	Sex-related differences in murine hepatic transcriptional and proteomic responses to TCDD. *Toxicology and Applied Pharmacology*, **2015**, 284, 188-96	4.6	16
152	Pathway and network analysis of cancer genomes. *Nature Methods*, **2015**, 12, 615-621	21.6	235
151	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. *Nature Genetics*, **2015**, 47, 367-372	36.3	292
150	Male and female mice show significant differences in hepatic transcriptomic response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. *BMC Genomics*, **2015**, 16, 625	4.5	25
149	The path to routine use of genomic biomarkers in the cancer clinic. *Genome Research*, **2015**, 25, 1508-13	9.7	26
148	A Progesterone-CXCR4 Axis Controls Mammary Progenitor Cell Fate in the Adult Gland. *Stem Cell Reports*, **2015**, 4, 313-322	8	29
147	Transcriptional profiling of rat white adipose tissue response to 2,3,7,8-tetrachlorodibenzo-□dioxin. *Toxicology and Applied Pharmacology*, **2015**, 288, 223-31	4.6	8
146	Spatial genomic heterogeneity within localized, multifocal prostate cancer. *Nature Genetics*, **2015**, 47, 736-45	36.3	306
145	Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection. *Nature Methods*, **2015**, 12, 623-30	21.6	201

144	ISOpureR: an R implementation of a computational purification algorithm of mixed tumour profiles. *BMC Bioinformatics*, **2015**, 16, 156	3.6	21
143	How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models. *Mutation Research - Reviews in Mutation Research*, **2015**, 764, 16-30	7	132
142	Transcriptional profiling of rat hypothalamus response to 2,3,7,8-tetrachlorodibenzo-□dioxin. *Toxicology*, **2015**, 328, 93-101	4.4	9
141	A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. *Nature Communications*, **2015**, 6, 10001	17.4	199
140	Integrating RAS status into prognostic signatures for adenocarcinomas of the lung. *Clinical Cancer Research*, **2015**, 21, 1477-86	12.9	11
139	VennDIS: a JavaFX-based Venn and Euler diagram software to generate publication quality figures. *Proteomics*, **2015**, 15, 1239-44	4.8	27
138	Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus. *Rheumatology*, **2015**, 54, 449-57	3.9	28
137	Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature*, **2015**, 517, 576-82	50.4	2332
136	The transcriptomic profile of ovarian cancer grading. *Cancer Medicine*, **2015**, 4, 56-64	4.8	2
135	Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers. *PLoS ONE*, **2015**, 10, e0121872	3.7	17
134	Developing a prognostic micro-RNA signature for human cervical carcinoma. *PLoS ONE*, **2015**, 10, e0123946	3.7	24
133	Identification of a microRNA signature associated with risk of distant metastasis in nasopharyngeal carcinoma. *Oncotarget*, **2015**, 6, 4537-50	3.3	40
132	miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD). *Oncotarget*, **2015**, 6, 22439-51	3.3	27
131	A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials. *Oncotarget*, **2015**, 6, 31693-701	3.3	4
130	Onco-proteogenomics: cancer proteomics joins forces with genomics. *Nature Methods*, **2014**, 11, 1107-13	21.6	102
129	Toward better benchmarking: challenge-based methods assessment in cancer genomics. *Genome Biology*, **2014**, 15, 462	18.3	29
128	Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. *Nature Communications*, **2014**, 5, 5203	17.4	164
127	Ensemble analyses improve signatures of tumour hypoxia and reveal inter-platform differences. *BMC Bioinformatics*, **2014**, 15, 170	3.6	19

126	SeqControl: process control for DNA sequencing. *Nature Methods*, **2014**, 11, 1071-5	21.6	6
125	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. *Nature Genetics*, **2014**, 46, 1166-9	36.3	150
124	ShatterProof: operational detection and quantification of chromothripsis. *BMC Bioinformatics*, **2014** , 15, 78	3.6	42
123	Systematic analysis of 18F-FDG PET and metabolism, proliferation and hypoxia markers for classification of head and neck tumors. *BMC Cancer*, **2014**, 14, 130	4.8	16
122	Next-generation sequencing of urologic cancers: next is now. *European Urology*, **2014**, 66, 4-7	10.2	7
121	Epigenetics in radiotherapy: where are we heading?. *Radiotherapy and Oncology*, **2014**, 111, 168-77	5.3	36
120	Use of Sequenom sample ID Plus SNP genotyping in identification of FFPE tumor samples. *PLoS ONE*, **2014**, 9, e88163	3.7	12
119	Identification of reference proteins for Western blot analyses in mouse model systems of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) toxicity. *PLoS ONE*, **2014**, 9, e110730	3.7	5
118	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. *Lancet Oncology, The*, **2014**, 15, 1521-1532	21.7	218
117	Cross-species transcriptomic analysis elucidates constitutive aryl hydrocarbon receptor activity. *BMC Genomics*, **2014**, 15, 1053	4.5	7
116	Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer. *BMC Pharmacology & Toxicology*, **2014**, 15, 66	2.6	21
115	Global optimization of somatic variant identification in cancer genomes with a global community challenge. *Nature Genetics*, **2014**, 46, 318-319	36.3	36
114	Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells. *Oncogene*, **2014**, 33, 2375-84	7.4	72
113	Haploinsufficiency of an RB-E2F1-Condensin II complex leads to aberrant replication and aneuploidy. *Cancer Discovery*, **2014**, 4, 840-53	24.4	57
112	Integrated omic analysis of oropharyngeal carcinomas reveals human papillomavirus (HPV)-dependent regulation of the activator protein 1 (AP-1) pathway. *Molecular and Cellular Proteomics*, **2014**, 13, 3572-84	7.6	13
111	Identification of genes expressed by immune cells of the colon that are regulated by colorectal cancer-associated variants. *International Journal of Cancer*, **2014**, 134, 2330-41	7.5	28
110	Novel PRKD gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. *Genes Chromosomes and Cancer*, **2014**, 53, 845-56	5	102
109	TCDD dysregulation of 13 AHR-target genes in rat liver. *Toxicology and Applied Pharmacology*, **2014**, 274, 445-54	4.6	30

108	Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells. *Breast Cancer Research and Treatment*, **2014**, 143, 301-12	4.4	43
107	NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer. *Oncotarget*, **2014**, 5, 11081-90	3.3	25
106	Microarray-Based Investigations in Cancer **2014**, 87-106		
105	Computational purification of individual tumor gene expression profiles leads to significant improvements in prognostic prediction. *Genome Medicine*, **2013**, 5, 29	14.4	70
104	Computational approaches to identify functional genetic variants in cancer genomes. *Nature Methods*, **2013**, 10, 723-9	21.6	129
103	Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. *Lancet Oncology, The*, **2013**, 14, 327-34	21.7	221
102	Validating reference genes within a mouse model system of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) toxicity. *Chemico-Biological Interactions*, **2013**, 205, 63-71	5	7
101	Genome-wide gene expression profiling of stress response in a spinal cord clip compression injury model. *BMC Genomics*, **2013**, 14, 583	4.5	30
100	Long-term hemodynamic and molecular effects persist after discontinued renin-angiotensin system blockade in patients with type 1 diabetes mellitus. *Kidney International*, **2013**, 84, 1246-53	9.9	9
99	Predicting outcomes in radiation oncology--multifactorial decision support systems. *Nature Reviews Clinical Oncology*, **2013**, 10, 27-40	19.4	270
98	A case report and genetic characterization of a massive acinic cell carcinoma of the parotid with delayed distant metastases. *Case Reports in Oncological Medicine*, **2013**, 2013, 270362	0.9	4
97	MYC phosphorylation at novel regulatory regions suppresses transforming activity. *Cancer Research* , **2013**, 73, 6504-15	10.1	22
96	Identifying gene locus associations with promyelocytic leukemia nuclear bodies using immuno-TRAP. *Journal of Cell Biology*, **2013**, 201, 325-35	7.3	35
95	TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. *Clinical Cancer Research*, **2013**, 19, 5202-9	12.9	34
94	Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. *Cancer Medicine*, **2013**, 2, 916-24	4.8	22
93	Two phases of disulfide bond formation have differing requirements for oxygen. *Journal of Cell Biology*, **2013**, 203, 615-27	7.3	84
92	Systematic evaluation of medium-throughput mRNA abundance platforms. *Rna*, **2013**, 19, 51-62	5.8	61
91	MicroRNA-196b regulates the homeobox B7-vascular endothelial growth factor axis in cervical cancer. *PLoS ONE*, **2013**, 8, e67846	3.7	52

90	The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. *PLoS ONE*, **2013**, 8, e67876	3.7	25
89	Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients. *American Journal of Transplantation*, **2012**, 12, 1929-35	8.7	37
88	Inter-strain heterogeneity in rat hepatic transcriptomic responses to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). *Toxicology and Applied Pharmacology*, **2012**, 260, 135-45	4.6	25
87	The prognostic value of temporal in vitro and in vivo derived hypoxia gene-expression signatures in breast cancer. *Radiotherapy and Oncology*, **2012**, 102, 436-43	5.3	37
86	C-Terminal region of teneurin-1 co-localizes with dystroglycan and modulates cytoskeletal organization through an extracellular signal-regulated kinase-dependent stathmin- and filamin A-mediated mechanism in hippocampal cells. *Neuroscience*, **2012**, 219, 255-70	3.9	33
85	Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies. *Genome Medicine*, **2012**, 4, 84	14.4	14
84	Prophylactic valproic acid treatment prevents schizophrenia-related behaviour in Disc1-L100P mutant mice. *PLoS ONE*, **2012**, 7, e51562	3.7	21
83	Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. *Journal of Pathology*, **2012**, 227, 53-61	9.4	51
82	From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. *Journal of Pathology*, **2012**, 227, 286-97	9.4	142
81	Identification of a novel brain derived neurotrophic factor (BDNF)-inhibitory factor: regulation of BDNF by teneurin C-terminal associated peptide (TCAP)-1 in immortalized embryonic mouse hypothalamic cells. *Regulatory Peptides*, **2012**, 174, 79-89		9
80	Epigenetic markers of prostate cancer in plasma circulating DNA. *Human Molecular Genetics*, **2012**, 21, 3619-31	5.6	42
79	Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. *Molecular and Cellular Proteomics*, **2012**, 11, 1870-84	7.6	62
78	Independent and functional validation of a multi-tumour-type proliferation signature. *British Journal of Cancer*, **2012**, 107, 508-15	8.7	9
77	Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation. *Molecular and Cellular Biology*, **2012**, 32, 3913-24	4.8	29
76	A Pilot Study Comparing HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas by Whole Exome Sequencing. *ISRN Oncology*, **2012**, 2012, 809370		28
75	NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data. *Bioinformatics*, **2012**, 28, 1546-8	7.2	168
74	Interspecies Heterogeneity in the Hepatic Transcriptomic Response to AHR Activation by Dioxin **2011**, 217-227		
73	Role of the AHR and its Structure in TCDD Toxicity **2011**, 179-196		4

72	Hepatic transcriptomic responses to TCDD in dioxin-sensitive and dioxin-resistant rats during the onset of toxicity. *Toxicology and Applied Pharmacology*, **2011**, 251, 119-29	4.6	38
71	Teneurin C-terminal associated peptide (TCAP)-1 modulates dendritic morphology in hippocampal neurons and decreases anxiety-like behaviors in rats. *Physiology and Behavior*, **2011**, 104, 199-204	3.5	29
70	VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in R. *BMC Bioinformatics*, **2011**, 12, 35	3.6	1098
69	In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry. *Journal of Proteome Research*, **2011**, 10, 2286-99	5.6	63
68	Molecular markers of injury in kidney biopsy specimens of patients with lupus nephritis. *Journal of Molecular Diagnostics*, **2011**, 13, 143-51	5.1	21
67	A tree-based approach for motif discovery and sequence classification. *Bioinformatics*, **2011**, 27, 2054-617.2		4
66	Unsupervised detection of genes of influence in lung cancer using biological networks. *Bioinformatics*, **2011**, 27, 3166-72	7.2	10
65	Role of Pirh2 in mediating the regulation of p53 and c-Myc. *PLoS Genetics*, **2011**, 7, e1002360	6	51
64	mRNA levels in control rat liver display strain-specific, hereditary, and AHR-dependent components. *PLoS ONE*, **2011**, 6, e18337	3.7	7
63	International network of cancer genome projects. *Nature*, **2010**, 464, 993-8	50.4	1613
62	LTR: Linear Cross-Platform Integration of Microarray Data. *Cancer Informatics*, **2010**, 9, 197-208	2.4	2
61	Re: Gene expression-based prognostic signatures in lung cancer: ready for clinical use?. *Journal of the National Cancer Institute*, **2010**, 102, 1677-8; author reply 1678-9	9.7	7
60	Dysregulation of the mevalonate pathway promotes transformation. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 15051-6	11.5	264
59	Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2). *Molecular Pharmacology*, **2010**, 78, 175-85	4.3	89
58	Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma. *Blood*, **2010**, 115, 4787-97	2.2	71
57	Aryl hydrocarbon receptor (AHR)-regulated transcriptomic changes in rats sensitive or resistant to major dioxin toxicities. *BMC Genomics*, **2010**, 11, 263	4.5	40
56	Characterization of the apoptotic response of human leukemia cells to organosulfur compounds. *BMC Cancer*, **2010**, 10, 351	4.8	8
55	Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents. *International Journal of Cancer*, **2010**, 127, 2936-48	7.5	43

54	Prognostic gene signatures for non-small-cell lung cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 2824-8	11.5	159
53	Dioxin-dependent and dioxin-independent gene batteries: comparison of liver and kidney in AHR-null mice. *Toxicological Sciences*, **2009**, 112, 245-56	4.4	45
52	Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. *Human Molecular Genetics*, **2009**, 18, 3227-43	5.6	145
51	Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. *Cancer Cell*, **2009**, 16, 533-46	24.3	178
50	Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. *Laboratory Investigation*, **2009**, 89, 597-606	5.9	205
49	Transcriptomic responses to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in liver: comparison of rat and mouse. *BMC Genomics*, **2008**, 9, 419	4.5	68
48	Genome-wide effects of acute progressive feed restriction in liver and white adipose tissue. *Toxicology and Applied Pharmacology*, **2008**, 230, 41-56	4.6	19
47	Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function. *Cancer Research*, **2008**, 68, 6688-97	10.1	46
46	Aryl hydrocarbon receptor-dependent induction of flavin-containing monooxygenase mRNAs in mouse liver. *Drug Metabolism and Disposition*, **2008**, 36, 2499-505	4	38
45	Optimization of experimental design parameters for high-throughput chromatin immunoprecipitation studies. *Nucleic Acids Research*, **2008**, 36, e144	20.1	26
44	Patterns of dioxin-altered mRNA expression in livers of dioxin-sensitive versus dioxin-resistant rats. *Archives of Toxicology*, **2008**, 82, 809-30	5.8	33
43	Web-based resources for clinical bioinformatics. *Methods in Molecular Medicine*, **2008**, 141, 309-29		
42	Comparison of Machine Learning and Pattern Discovery Algorithms for the Prediction of Human Single Nucleotide Polymorphisms **2007**,		2
41	Three-gene prognostic classifier for early-stage non small-cell lung cancer. *Journal of Clinical Oncology*, **2007**, 25, 5562-9	2.2	195
40	Changes in gene expression induced by tienilic Acid and sulfamethoxazole: testing the danger hypothesis. *Journal of Immunotoxicology*, **2007**, 4, 253-66	3.1	15
39	Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma. *Molecular Cancer Therapeutics*, **2007**, 6, 1886-97	6.1	54
38	CUL7 is a novel antiapoptotic oncogene. *Cancer Research*, **2007**, 67, 9616-22	10.1	45
37	microRNAs in adult rodent liver are refractory to dioxin treatment. *Toxicological Sciences*, **2007**, 99, 470-87	4.4	72

36	Evaluation of various housekeeping genes for their applicability for normalization of mRNA expression in dioxin-treated rats. *Chemico-Biological Interactions*, **2006**, 160, 134-49	5	51
35	Microarray analysis of the developing cortex. *Journal of Neurobiology*, **2006**, 66, 1646-58		38
34	dbZach: A MIAME-compliant toxicogenomic supportive relational database. *Toxicological Sciences*, **2006**, 90, 558-68	4.4	35
33	Differential expression profiling of the hepatic proteome in a rat model of dioxin resistance: correlation with genomic and transcriptomic analyses. *Molecular and Cellular Proteomics*, **2006**, 5, 882-94	7.6	48
32	Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity. *Clinical Cancer Research*, **2006**, 12, 5632-40	12.9	114
31	Aryl hydrocarbon receptor regulates distinct dioxin-dependent and dioxin-independent gene batteries. *Molecular Pharmacology*, **2006**, 69, 140-53	4.3	263
30	The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. *Cancer Research*, **2006**, 66, 5330-7	10.1	384
29	CpG Island microarray probe sequences derived from a physical library are representative of CpG Islands annotated on the human genome. *Nucleic Acids Research*, **2005**, 33, 2952-61	20.1	82
28	Gene expression profiling in a model of D-penicillamine-induced autoimmunity in the Brown Norway rat: predictive value of early signs of danger. *Chemical Research in Toxicology*, **2005**, 18, 1193-202	4	13
27	Polymorphisms of human nuclear receptors that control expression of drug-metabolizing enzymes. *Pharmacogenetics and Genomics*, **2005**, 15, 371-9	1.9	26
26	Toxicological implications of polymorphisms in receptors for xenobiotic chemicals: the case of the aryl hydrocarbon receptor. *Toxicology and Applied Pharmacology*, **2005**, 207, 43-51	4.6	98
25	Unsupervised pattern recognition: an introduction to the whys and wherefores of clustering microarray data. *Briefings in Bioinformatics*, **2005**, 6, 331-43	13.4	82
24	Pharmacogenomics. *Drugs and the Pharmaceutical Sciences*, **2005**, 515-556		
23	PUNS: transcriptomic- and genomic-in silico PCR for enhanced primer design. *Bioinformatics*, **2004**, 20, 2399-400	7.2	23
22	Dioxin-responsive AHRE-II gene battery: identification by phylogenetic footprinting. *Biochemical and Biophysical Research Communications*, **2004**, 321, 707-15	3.4	78
21	DreamAI: algorithm for the imputation of proteomics data		3
20	Somatic Mutations and Risk-Variants Converge on Cis-Regulatory Elements to Reveal the Cancer Driver Transcription Regulators in Primary Prostate Tumors. *SSRN Electronic Journal*,	1	2
19	Combining accurate tumour genome simulation with crowd-sourcing to benchmark somatic structural variant detection		1

18	Sex Differences in Oncogenic Mutational Processes	2
17	A comprehensive multicenter comparison of whole genome sequencing pipelines using a uniform tumor-normal sample pair	5
16	Nanocall: An Open Source Basecaller for Oxford Nanopore Sequencing Data	10
15	BPG: Seamless, Automated and Interactive Visualization of Scientific Data	7
14	The evolutionary history of 2,658 cancers	28
13	Age Influences on the Molecular Presentation of Tumours	2
12	Tumor cell total mRNA expression shapes the molecular and clinical phenotype of cancer	2
11	Candidate cancer driver mutations in superenhancers and long-range chromatin interaction networks	5
10	Integrated single-nucleotide and structural variation signatures of DNA-repair deficient human cancers	3
9	Best Practices for Benchmarking Germline Small Variant Calls in Human Genomes	13
8	The Origins and Consequences of Localized and Global Somatic Hypermutation	5
7	Network-Based Biomarkers Enable Cross-Disease Biomarker Discovery	1
6	Creating Standards for Evaluating Tumour Subclonal Reconstruction	3
5	Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes	25
4	Fast Nonnegative Matrix Factorization and Applications to Pattern Extraction, Deconvolution and Imputation	1
3	Quantifying the Influence of Mutation Detection on Tumour Subclonal Reconstruction	2
2	Identifying TCDD-resistance genes via murine and rat comparative genomics and transcriptomics	1
1	A robust benchmark for germline structural variant detection	34